未知股票 ABP 深 沪
等待开盘
--
0.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 --
- 最 低 --
- 昨 收 --
- 总市值 0
- 52周最高 --
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 --
- 委 比 0.00%
- 总股本 271.63万
- 历史最高 --
- 量 比 0
- 振 幅 NaN.00%
- 历史最低 --
- 每 手 1
- 风险率 4.14%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Is Abpro Holdings Inc Gaining or Losing Market Support?
Abpro Holdings Inc's (NYSE:ABP) short interest as a percent of float has risen ...
02-12 23:00
Why Fastly Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
Shares of Fastly Inc (NASDAQ:FSLY) rose sharply in pre-market trading after the...
02-12 17:31
Market-Moving News for February 10th
SPOT: 16% | Spotify Technology shares are trading higher after reporting better-than-expected Q4 financial results and strong Q1 MAU outlook. ABP: 19% | Abpro Holdings shares are trading
02-10 20:16
Abpro Holdings FormSCHEDULE 13G Shows THE GOLDMAN SACHS GROUP Has 6.8% Stake In Co.
-SEC Filing
02-10 05:17
Abpro and Celltrion to Start Global Trial of Targeted HER2+ Cancer Antibody in Early 2026
Abpro Holdings, Inc. (NASDAQ:ABP), a biotechnology company developing next-generation antibody therapeutics for solid tumors, today announced, together with its co-development partner Celltrion, Inc., that the U.S. Food
01-06 20:09
Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72
Abpro Holdings, Inc. and Celltrion, Inc. announced the FDA clearance of the IND application for ABP-102 / CT-P72, a multispecific HER2 × CD3 T-cell engager targeting HER2-positive solid tumors. This clearance enables the initiation of a Phase 1 clinical trial in the first half of 2026 to evaluate safety, tolerability, pharmacokinetics, and efficacy. ABP-102 / CT-P72 is designed to selectively target HER2-overexpressing tumor cells while engaging ...
01-06 12:00
Abpro Holdings Submits IND Application for Cancer Drug
An announcement from Abpro Holdings ( ($ABP) ) is now available. On December 15...
2025-12-15 20:50
Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives
Abpro Holdings, a biotechnology company, received a Nasdaq extension to regain compliance with listing requirements. The company has reduced operating expenses by ~60% and completed a reverse stock split. It plans to increase shareholders’ equity via flexible financing and achieve long-term milestones. Lead candidate ABP-102 is on track for first-in-human trials in 2026. Abpro remains focused on executing its compliance plan while advancing its p...
2025-12-09 12:00
Abpro To Present Data For CT-P72/ABP-102 Tetravalent Bispecific Antibody At Society For Immunotherapy Of Cancer
Abpro Corporation (Nasdaq: ABP) ("Abpro") and Celltrion, Inc. ("Celltrion") today announced that they will present new preclinical data for CT-P72/ABP-102, a tetravalent bispecific antibody targeting HER2 and CD3, at the
2025-11-04 22:17
Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025
Abpro Holdings, Inc. implemented a 1-for-30 reverse stock split to comply with Nasdaq listing standards and support future growth. The company reduced its operating costs by ~60% and is leveraging its DiversImmune® platform to enhance pipeline value. The reverse split reduced outstanding shares from 81.2 million to 2.7 million under the ticker symbol "ABP." Abpro aims to efficiently create long-term shareholder value through its leaner structure,...
2025-11-03 12:00
